CRISPR/Cas9-mediated Cxcr4 Disease Allele Inactivation for Gene Therapy in a Mouse Model of WHIM Syndrome
Blood · 2023
DOI: 10.1182/blood.2022019142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Ji-Liang Gao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Signaling Section, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health…. Hauptthemen laut MEDLINE: Warts, Immunologic Deficiency Syndromes. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
WHIM syndrome is an autosomal dominant immunodeficiency disorder caused by gain-of-function mutations in chemokine receptor CXCR4 that promote severe panleukopenia due to bone marrow (BM) retention of mature leukocytes. We previously reported that Cxcr4-haploinsufficient (Cxcr4+/o) hematopoietic stem cells (HSCs) have a strong selective advantage for durable hematopoietic reconstitution over wildtype (Cxcr4+/+) and WHIM (Cxcr4+/w) HSCs, and that a WHIM patient was spontaneously cured by chromothriptic deletion of the disease allele in an HSC, suggesting that WHIM allele inactivation through gene editing may be a safe genetic cure strategy for the disease. We have now developed a two-step preclinical protocol of autologous hematopoietic stem and progenitor cell (HSPC) transplantation towards this goal. First, one copy of Cxcr4 in HSPCs was inactivated in vitro by CRISPR/Cas9 editing with a single guide RNA (sgRNA) that does not discriminate between WHIM and wildtype Cxcr4 alleles. Then, through in vivo natural selection, WHIM allele-inactivated cells were enriched over wildtype allele-inactivated cells. The WHIM allele-inactivated HSCs retained long-term pluripotency and selective hematopoietic reconstitution advantages. To our knowledge this is the first example of gene therapy for an autosomal dominant gain-of-function disease using a disease allele inactivation strategy in place of the less efficient disease allele repair approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Molecular Signaling Section, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
- Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
ORCID-Profile: David H McDermott, Shamik Majumdar, Colin L Sweeney, Harry L Malech
Zitieren
APA
Gao, J. L., Owusu-Ansah, A., Yang, A., Yim, E., McDermott, D. H., Jacobs, P., Majumdar, S., Choi, U., Sweeney, C. L., Malech, H. L., & Murphy, P. M. (2023). CRISPR/Cas9-mediated Cxcr4 Disease Allele Inactivation for Gene Therapy in a Mouse Model of WHIM Syndrome. Blood. https://doi.org/10.1182/blood.2022019142
Vancouver
Gao JL, Owusu-Ansah A, Yang A, Yim E, McDermott DH, Jacobs P, et al. CRISPR/Cas9-mediated Cxcr4 Disease Allele Inactivation for Gene Therapy in a Mouse Model of WHIM Syndrome. Blood. 2023. doi:10.1182/blood.2022019142
BibTeX
@article{Gao2023,
author = {Gao, Ji-Liang and Owusu-Ansah, Albert and Yang, Alexander and Yim, Erin and McDermott, David H and Jacobs, Paejonette and Majumdar, Shamik and Choi, Uimook and Sweeney, Colin L and Malech, Harry L and Murphy, Philip M},
title = {CRISPR/Cas9-mediated Cxcr4 Disease Allele Inactivation for Gene Therapy in a Mouse Model of WHIM Syndrome},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022019142}
}
EUVIMED